EpiVax unveils a new vaccine

EpiVax Inc., a Providence-based biotechnology firm, last week announced it has developed a promising vaccine against tularemia. In animal studies at Rhode Island Hospital, the firm said, its TuliVaxTM protected against lethal doses of the disease. Stephen Gregory, an associate professor at Brown University's School of Medicine, used mice with "humanized" immune systems; the mice…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -